“By highlighting the devastating human impact of forced medication tapers and limited access to care, Pharmacist Steve’s observations serve as a formal plea for Congressional oversight to restore a patient-centered medical model.”
youarewithinthenorms.com
NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC., SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS, MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., M.B.A., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, IN THE SPIRIT OF WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, IN THE SPIRIT OF WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
THE SILENT CRISIS
An abstract graphic contrasting pathways and neural imagery, featuring the title ‘The Silent Crisis: Over-Federalization, Simplistic Metrics, and the Death of Clinical Autonomy’ with a subtitle about analyzing pain management policy.
ACCORDING TO PHARMACIST STEVE
This open letter from a veteran pharmacist of 52 years addresses a systemic breakdown in chronic pain management caused by excessive government oversight and corporate interference.
The author, Pharmacist Steve Ariens, of the Blog Pharmacist Steve, argues that rigid regulations and the dominance of Pharmacy Benefit Managers have stripped healthcare providers of their autonomy, transforming them into reluctant gatekeepers who must prioritize compliance over compassion.
By documenting the human impact of these policies, Pharmacist Steve’s letter serves as an urgent plea to restore accountability and compassion to the pharmaceutical supply chain. Ultimately, the document critiques a bureaucratic culture where administrative mandates supersede clinical judgment, leading to a silent crisis for the most vulnerable members of society.
THE SILENT CRISIS FOR CHRONIC PAIN PATIENTS AND PHARMACISTS
According to Pharmacist Steve, the “Silent Crisis” is a systemic breakdown in chronic pain management caused by the transformation of the U.S. healthcare system into a maze of bureaucracy, regulatory overreach, and corporate control. It is characterized by administrative mandates and middleman interference that increasingly supersede professional clinical judgment, endangering lives and eroding the heart of compassionate care.
The crisis is driven by several converging factors:
The Great Medical Tug-of-War’ illustrates the shift from administrative compliance to the criminalization of clinical judgment. It features two layers: the Clinical Layer, highlighting professional autonomy and historical norms, and the Bureaucratic Layer, detailing federal police power and the current realities of criminal prosecution.
THE GREAT MEDICAL TUG-OF-WAR FROM COMPLIANCE TO THE CRIMINALIZATION OF CLINICAL JUDGMENT
According to Pharmacist Steve, federal agencies currently focus on a “corrosive transformation” of tracking prescribing volume rather than actual patient outcomes, creating a “metric vacuum” that hides the true scale of the crisis facing chronic pain patients.
The specific metrics that are currently uncounted or missing official tracking in federal policy include:
- Suicides directly linked to restrictive laws or forced medication tapers.
- Loss of Functionality: The number of patients who lose their ability to perform activities of daily living.
- Employment and Disability: The number of patients forced to stop working and apply for disability due to unmanaged pain.
- Secondary Medical Complications: Deaths from medical complications such as strokes or heart attacks caused by the physiological stress of forced tapers.
- Unmet Clinical Needs: While programs like Medicaid Lock-Ins track reductions in medical spending, it is currently “not clear” if these represent appropriate clinical reductions or simply unmet needs for care for vulnerable patients.
- Non-Clinical Events: Administrative systems like Medicaid claims are unable to observe drug diversion or overdose events that do not generate a formal medical claim.
Over-Federalization: There has been a shift from traditional civil audits to aggressive criminal prosecution of healthcare providers, effectively criminalizing medical subjectivity and treating professional disagreements as felony fraud.
According to Pharmacist Steve, who has been licensed for more than 50 years, pharmacy practice has shifted from a patient-centered model to one dominated by bureaucratic compliance, regulatory overreach, and corporate control. Pharmacist Steve, this transformation has turned practitioners into “gatekeepers, rationers, and witnesses to preventable tragedy” who must prioritize complex, ever-changing mandates from agencies and middlemen over compassionate care
Pharmacist Steve argues that by focusing on reducing the number of prescriptions rather than these human costs, the government ignores the “clinical reality of patient harm.”
Bureaucratic and Regulatory Interference
- The Climate of Fear: Reforms like the 2016 CDC Guidelines introduced sweeping opioid restrictions and rigid dosage caps. These rules, adopted by dozens of agencies, often ignore individual patient needs and pharmacogenetics, creating a “climate of fear” for both patients and providers.
- The “Emergency Loophole”: Federal agencies have used Public Health Emergency declarations to bypass 42 U.S.C. § 1395, a statute intended to prohibit federal officers from exercising “supervision or control” over the practice of medicine.
- Over-Federalization: There has been a shift from traditional civil audits toward aggressive criminal prosecution of healthcare providers, effectively criminalizing medical subjectivity and treating professional disagreements as felony fraud.
The dominance of Middlemen
- PBM Control: The Pharmacy Benefit Manager (PBM) industry now dominates the prescription supply chain, imposing opaque pricing and onerous administrative tasks that drive up costs for patients while siphoning billions of dollars from the system.
- Algorithmic Gatekeeping: Payers and PBMs use “Point of Sale” solutions to aggressively manage opioid utilization. These systems calculate Morphine Equivalent Dose (MED) in real-time and use customizable thresholds to flag or route prescriptions for review, often prioritizing economic savings over clinical appropriateness.
Illustrating the conflict between metrics and medical practices in clinical autonomy and pain management, highlighting key statistics, regulatory oversight, and the impact on healthcare professionals and patients.
Devastating Human and Clinical Impact
- Patients as “Untouchables”: Chronic pain patients, who are often elderly, disabled, or financially at-risk, are being cast aside as “untouchables”. They face forced medication tapers, pharmacy shortages, and a collapse of provider access due to legal raids and regulatory scrutiny.
- Severe Health Outcomes: These systemic barriers lead to unmanageable pain, medical emergencies, withdrawal, and, in far too many cases, loss of hope and suicide. Current federal policy focuses on reducing prescription volume rather than tracking these “human costs”.
- Provider Role Shift: Pharmacists and prescribers have been forced out of their clinical roles and into the roles of “gatekeepers, rationers, and witnesses to preventable tragedy”.
The Failure of Protective Metrics
Research into Medicaid Lock-In Programs (MLIPs), which are intended to minimize abuse by “locking” high-risk patients to a single provider and pharmacy, highlights the flaws in this bureaucratic approach. The “simplistic opioid use thresholds” often used to flag patients for these programs are poor predictors of risk, failing to capture 75% of patients who actually experience a preventable overdose. This suggests that current policies may limit public health benefits by focusing on the wrong metrics.
ACCORDING TO PHARMACIST STEVE, “THE FEDERAL TUG OF WAR”
PHARMACIST STEVE DICUSSES THE WHATS AND IMPACTING DANGERS OF Morphine milligram equivalent dosing
According to Pharmacist Steve, the Morphine Equivalent Dose (MED), also referred to as Morphine Milligram Equivalents (MME), is a clinical and regulatory metric used to standardize the potency of various opioid medications by comparing them to a reference dose of morphine. While intended as a tool for managing patient safety, the sources highlight significant debate regarding its effectiveness as a predictive metric and the human cost of its use in rigid federal policies.
Clinical and Regulatory Application
MED serves as a management tool to identify potential risks in opioid utilization by calculating both individual and cumulative doses. It establishes “equianalgesic” doses—the amount of a specific drug needed to achieve the same pain-relieving effect as a reference dose of morphine. For example, using 30 mg of oral morphine as a baseline, equivalent doses include:
- Hydromorphone: 7.5 mg
- Oxycodone: 20 mg
- Hydrocodone: 30 mg
- Tramadol: 300 mg
- Fentanyl (transdermal): 12.5 mcg/hr
Administrative systems, such as those used by Pharmacy Benefit Managers (PBMs), utilize these calculations to implement “Point of Sale” solutions. These systems calculate a patient’s MED in real-time and use customizable thresholds—often set at 50, 90, or 120 mg MED—to flag safety concerns or route prescriptions for further bureaucratic review before they can be dispensed.
Effectiveness as a Safety Metric
Research indicates that “simplistic” MED thresholds are often poor predictors of actual public health outcome. A study on Medicaid populations found that while certain thresholds (like ≥5 opioid claims) successfully flagged “high utilizers,” they were far less effective at predicting danger:
- Failure to Capture Risk: One analysis showed that while a common threshold flagged 8% of opioid users, it failed to capture 75% of patients who actually went on to experience a preventable overdose.
- Nuance vs. Rigid Caps: The research suggests that finding the highest-risk patients requires nuance—such as smarter predictive modeling and provider insights—rather than relying solely on simple dose-based “red flags”.
The Human Cost of Rigid Thresholds
The sources argue that the “over-federalization” of medicine has transformed MED from a clinical guideline into a rigid regulatory cap. Policies like the 2016 CDC Guidelines codified these thresholds into sweeping restrictions that often ignore individual clinical reality and pharmacogenetics.
The resulting impact on chronic pain patients is described as a “Silent Crisis”:
- Forced Tapers: Strict adherence to MED caps has led to forced medication reductions, which can cause physiological collapse, withdrawal, and medical emergencies like strokes or heart attacks.
- Uncounted Metrics: Federal policy currently focuses on reducing “prescribing volume” (total MED dispensed) but fails to track the human costs, such as suicides linked to restrictive laws or the number of patients who lose the ability to perform activities of daily living.
- Provider Role Shift: Pharmacists and doctors are increasingly forced out of their clinical roles and into serving as “gatekeepers and rationers” who must prioritize administrative compliance over the stability and dignity of their patients.
In contrast to these rigid models, proposed reform frameworks like the NCP3 advocate for restoring clinical autonomy and using sound medical literature, such as the ASIPP 2023 Consensus Guidelines, to manage complex pain care rather than relying on politically driven dosage caps
Graphic discussing the variability of Daily MME as a clinical metric, emphasizing its subjective nature and implications for patients and policymakers.
How do payers WRONGFULLY use MME to SO-CALLED manage patient safety?
According to Pharmacist Steve, payers use the Morphine Equivalent Dose (MED) as a critical management tool to mitigate risks, identify issues in opioid utilization, and ensure clinical appropriateness.
Disturbingly, Pharmacist has pointed out that payers manage and endanger patient healthcare safety through several key MED-based strategies:
- Real-Time Point-of-Sale Monitoring: Payers implement solutions that calculate both individual and cumulative MED (the total potency of all opioids a patient is taking) at the moment a prescription is filled. This allows for real-time alerts to be sent to the payer or client regarding potential safety concerns.
- Customizable Thresholds and Clinical Routing: Payers establish specific dose thresholds—often using the 50–120 mg MED range as a primary indicator of risk. When a prescription exceeds these “magic numbers,” the system can automatically route the claim for a detailed clinical review to determine if the dose is medically necessary.
- Clinical Intervention and Weaning: Payers look for indicators of clinically meaningful functional improvement. If a patient is on a high dose without a clear medical indication or improvement, the payer may recommend that the healthcare team wean the patient off the medication.
- Retrospective Review and Red Flagging: Beyond real-time alerts, payers conduct retrospective assessments of patient and prescriber data. This helps identify “red flags,” such as doctor shopping or inappropriate prescribing behaviors that might not be visible during a single transaction.
- Triage into Management Programs: High MED data is used to triage patients into comprehensive pain management programs. One case study noted that implementing a point-of-sale MED solution led to a 51.5% decrease in the count of prescriptions at or above 120 MED.
- Predictive Modeling: Advanced payers are moving toward predictive analytics that score a patient’s risk based on their behavioral profile and track changes in that risk over time, allowing for more nuanced interventions than simple dose thresholds provide.
Payers also follow and incorporate the scientifically flawed, dangerous CDC Opioid guidelines “best practices” by collaborating closely with pharmacy benefit managers (PBMs) and leveraging data from State Prescription Drug Monitoring Programs (PDMPs) to get a more complete picture of a patient’s care.
THE STORY OF PRONTO PHARMACY, LLC, TAMPA, Florida
THE STORY OF NEUMANNS PHARMACY, LLC, TALLULAH, LOUISIANA
According to Pharmacist Steve, by rigorously applying these tests, the legal strategist ensures that the courtroom remains a sanctuary for truth rather than a stage for methodologically unvalidated advocacy.
🔓 🔓 🔓
ALL WATCHED OVER BY MACHINES OF LOVING GRACE
OUR TREE OF KNOWLEDGE SHALL NEVER BE SUPPRESSED
FOR NOW
THE NORMS
REFERENCES:
